Keisuke Izumi

Dr. Keisuke Izumi

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TSTatsuya Shimada
Tatsuya Shimada
MHMisako Higashida-Konishi
Misako Higashida-Konishi
KIKeisuke Izumi
Keisuke Izumi
SHSatoshi Hama
Satoshi Hama
TOTatsuhiro Oshige
Tatsuhiro Oshige
YOYutaka Okano
Yutaka Okano
Immunosuppressive treatment is a common cause of cytomegalovirus (CMV) reactivation. However, there is no consensus regarding the risk factors for CMV reactivation in rheumatic diseases. Therefore, this study aimed to elucidate the risk factors associated with CMV reactivation. We retrospectively collected the data of 472 patients with rheumatic diseases whose CMV pp65 antigen (C7-HRP) titer was measured. We divided the patients into those with and those without C7-HRP. We retrospectively collected data on age, sex, primary condition and organ involvement, and blood test results. We also investigated the use of immunosuppressants and the maximum and cumulative doses of prednisolone (PSL). We performed univariate and multivariate analyses to identify risk factors for CMV reactivation. Multivariate analysis showed that higher age (71.2 vs. 64.4 years, p = 0.0022), hypoalbuminemia (2.9 vs. 3.4 g/dL, p = 0.0104), higher creatinine level (1.2 vs. 0.9 mg/dL, p = 0.0026), cyclosporine use (8.2 vs. 3.6%, p = 0.0101), and higher maximum (552.4 vs. 243.3 mg, p < 0.0001) and cumulative (2785.9 vs. 1330.5 mg, p < 0.0001) doses of PSL were associated with CMV reactivation. Older age, hypoalbuminemia, higher creatinine level, cyclosporine use, and higher maximum and cumulative doses of PSL were significant risk factors for CMV reactivation in rheumatic diseases.

27 November 2015 in RMD Open
Verified
Journal Article
Open access
PDF file
KIKeisuke Izumi
Keisuke Izumi
HKHarumi Kuda
Harumi Kuda
MUMari Ushikubo
Mari Ushikubo
MKMasataka Kuwana
Masataka Kuwana
TTTsutomu Takeuchi
Tsutomu Takeuchi
HOHisaji Oshima
Hisaji Oshima
Polymyalgia rheumatica (PMR) affects older people, and although glucocorticoids are effective in treating PMR, they frequently result in side effects. Therefore, we conducted a retrospective study to assess the effectiveness and safety of tocilizumab as an alternative to glucocorticoids. We included 13 consecutive patients with PMR (11 women and 2 men; median age, 74 years) diagnosed according to Bird's criteria and the 2012 European League Against Rheumatism/American College of Rheumatology provisional classification criteria. All patients received tocilizumab infusion (8 mg/kg every 4 weeks) at our institutions, between 2008 and 2014, because of PMR relapses (n=12) or insufficient response to initial prednisolone treatment (n=1), without increasing prednisolone dosage. Seven patients were on methotrexate, and all had one or more glucocorticoid-related comorbidities. Administration of tocilizumab significantly improved inflammation and PMR symptoms such as morning stiffness, as well as the Patient-Pain and Patient-Global Assessment visual analogue scales (p<0.05). Proximal muscle pain disappeared within 8 weeks, on average, and the Health Assessment Questionnaire-Disability Index scores (p=0.098) and concomitant prednisolone doses (p<0.05) decreased at 12 weeks. Severe adverse events were not observed during the mean tocilizumab treatment period of 43.4 weeks. Our findings suggest that tocilizumab is effective and safe for PMR treatment.

Verified
Journal Article
Open access
PDF file
KIKeisuke Izumi
Keisuke Izumi
OMOkinori Murata
Okinori Murata
MHMisako Higashida-Konishi
Misako Higashida-Konishi
YKYuko Kaneko
Yuko Kaneko
HOHisaji Oshima
Hisaji Oshima
TTTsutomu Takeuchi
Tsutomu Takeuchi
Polymyalgia rheumatica (PMR) is an inflammatory disorder characterized by pain and stiffness in the shoulders, hips, and proximal limbs; it usually affects elderly patients. The effectiveness of methotrexate and tocilizumab in PMR treatment has not been extensively studied. Thus, we aimed to assess the steroid-sparing effect of tocilizumab and methotrexate in PMR in clinical practice. Consecutive patients with PMR in our hospitals, who were included in our retrospective cohort, were reviewed between 2005 and 2015 and divided into the following groups according to their treatments: prednisolone or none (prednisolone group), methotrexate ± prednisolone (methotrexate group), or tocilizumab ± prednisolone (tocilizumab group). The prednisolone dose at the last follow-up was compared. A total of 227 patients with an average age of 74 years were enrolled. No difference in baseline characteristics was found among the three groups. The prednisolone dose at the last follow-up was lower (0 vs. 3.0 vs. 3.5 mg/day, p < 0.001) and the prednisolone discontinuation rate was higher (80.0% vs. 28.3% vs. 18.8%, p < 0.0001) in the tocilizumab group than in the prednisolone and methotrexate groups. This study suggested that tocilizumab has a steroid-sparing effect in PMR. Tocilizumab can be an option in the management of PMR. Future studies are warranted to confirm our findings.

24 October 2018 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
MHMichitaro Hayakawa
Michitaro Hayakawa
KIKeisuke Izumi
Keisuke Izumi
MHMisako Higashida-Konishi
Misako Higashida-Konishi
MUMari Ushikubo
Mari Ushikubo
MTMasako Tsukamoto
Masako Tsukamoto
HOHisaji Oshima
Hisaji Oshima

30 May 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
TYTetsuro Yoshimaru
Tetsuro Yoshimaru
MOMasaya Ono
Masaya Ono
YBYoshimi Bando
Yoshimi Bando
YCYi-An Chen
Yi-An Chen
KMKenji Mizuguchi
Kenji Mizuguchi
Toyomasa KatagiriToyomasa Katagiri
Toyomasa Katagiri
Approximately 70% of breast cancer cells express oestrogen receptor alpha (ERα). Previous studies have shown that the Brefeldin A-inhibited guanine nucleotide-exchange protein 3–prohibitin 2 (BIG3-PHB2) complex has a crucial role in these cells. However, it remains unclear how BIG3 regulates the suppressive activity of PHB2. Here we demonstrate that BIG3 functions as an A-kinase anchoring protein that binds protein kinase A (PKA) and the α isoform of the catalytic subunit of protein phosphatase 1 (PP1Cα), thereby dephosphorylating and inactivating PHB2. E2-induced PKA-mediated phosphorylation of BIG3-S305 and -S1208 serves to enhance PP1Cα activity, resulting in E2/ERα signalling activation via PHB2 inactivation due to PHB2-S39 dephosphorylation. Furthermore, an analysis of independent cohorts of ERα-positive breast cancers patients reveal that both BIG3 overexpression and PHB2-S39 dephosphorylation are strongly associated with poor prognosis. This is the first demonstration of the mechanism of E2/ERα signalling activation via the BIG3–PKA–PP1Cα tri-complex in breast cancer cells.

30 April 2020 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
MHMisako Higashida-Konishi
Misako Higashida-Konishi
KIKeisuke Izumi
Keisuke Izumi
MTMasako Tsukamoto
Masako Tsukamoto
HOHiroaki Ohya
Hiroaki Ohya
NTNozomi Takasugi
Nozomi Takasugi
HOHisaji Oshima
Hisaji Oshima